Viridian Therapeutics secured FDA approval for Lumvoa (veligrotug-vvze) for thyroid eye disease, covering both chronic and active phases. The decision also includes labeling and dosing updates designed to compete in the crowded TED market. Lumvoa’s approval positions Viridian against Amgen’s Tepezza (teprotumumab-trbw), which has been the only approved therapy since 2020. FDA clearance in TED is commercially significant because payer coverage and real-world adoption often hinge on dosing convenience and durability of response.